EN | UA
EN | UA

Help Support

Back

Comparison of intermediate and standard-dose prophylactic anticoagulation in COVID-19 patients in ICU

Comparison of intermediate and standard-dose prophylactic anticoagulation in COVID-19 patients in ICU Comparison of intermediate and standard-dose prophylactic anticoagulation in COVID-19 patients in ICU
Comparison of intermediate and standard-dose prophylactic anticoagulation in COVID-19 patients in ICU Comparison of intermediate and standard-dose prophylactic anticoagulation in COVID-19 patients in ICU

Thrombosis is regarded as one of the major extrapulmonary indications of COVID-19. 

See All

Key take away

The intermediate-dose when compared to the standard-dose prophylactic anticoagulation therapy didn't minimize extracorporeal membrane oxygenation (ECMO) therapy, thrombosis, and mortality in critically ill patients infected with the coronavirus.

Background

Thrombosis is regarded as one of the major extrapulmonary indications of COVID-19. An open-label randomized controlled trial (INSPIRATION) aimed to examine the ideal type and duration of the preventive antithrombotic therapy in COVID-19 patients with thrombosis admitted to the critical care unit.

Method

In total, 600 participants were subjected to either intermediate-dose or standard-dose prophylactic anticoagulation for 30 days, regardless of the hospital discharge status. Composite of adjudicated venous or arterial thrombosis, ECMO treatment, or all-cause mortality was the primary endpoint. Major bleeding was the main safety endpoint.

Result

Five hundred and sixty-two participants entered the modified intention-to-treat assessment, of whom 336 (59.8%) endured hospital discharge. The occurrence of primary endpoint and major bleeding events in subjects allocated to intermediate-dose and the standard-dose anticoagulation group is illustrated in the table below:

Conclusion

At 90-day follow-up, the intermediate dose did not decrease composite of death, ECMO treatment, or venous or arterial thrombosis as compared to the standard-dose prophylactic anticoagulation.

Source:

Thrombosis and Haemostasis

Article:

Intermediate vs Standard-dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to ICU: Ninety-day Results from the INSPIRATION Trial

Authors:

Behnood Bikdeli et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: